Navigation Links
Human Embryonic-Like Extracellular Matrix Significantly Inhibits Tumor Growth and Cancer Cell Proliferation
Date:6/17/2010

Studies of the human extracellular matrix (hECM) produced under proprietary conditions of hypoxia and suspension have demonstrated its ability to diminish or eliminate tumor load in melanoma, breast cancer, colon cancer and glioma, both in vitro and in vivo.

SAN DIEGO, CA (PRWEB) June 17, 2010 - Histogen, Inc., a regenerative medicine company developing solutions based on the products of newborn cells grown under embryonic conditions, will present findings tomorrow at the International Society for Stem Cell Research (ISSCR) Annual Meeting. Studies of the human extracellular matrix (hECM) produced under proprietary conditions of hypoxia and suspension have demonstrated its ability to diminish or eliminate tumor load in melanoma, breast cancer, colon cancer and glioma, both in vitro and in vivo.

Tumor growth was significantly inhibited across these cancer cell lines, with a 50-80% reduction in tumor weight seen in the tumor chorioallantoic membrane (tumcam) model (p<0.05) and a 70-90% reduction seen in subcutaneous mouse xenograft experiments (p<0.02). In studies of a carcinomatosis model established with a human colon carcinoma line, treatment with the hECM resulted in reduced tumor number and size, reduction of ascites, and, to date, a doubling in lifespan, as compared to untreated and cisplatin-treated mice.

"To see significant inhibition of multiple neoplastic cell lines, in multiple models, is a powerful indication of the future clinical potential of our embryonic-like extracellular matrix," said Dr. Mark Hubka, Histogen's Director of Clinical Affairs. "We are particularly excited about the potential utility of the hECM in rapidly progressing and debilitating cancers, such as carcinomatosis, where there are limited treatments that can offer an improvement in the quality and length of life."

Further studies of human colon adenocarcinoma have shown the ability of the hECM, when used to coat biopsy needles, to significantly reduce tumor seeding along the needle track (p=0.002) and prevent the development of secondary subcutaneous tumors. This represents a potential nearer-term application of the hECM in oncology.

"Our studies with hECM substantiate various reports which have shown that embryonic matrix proteins can selectively target the growth of cancer cells in vivo," said Emmett Pinney, Histogen's Director of Oncology. "We are excited about demonstrating the efficacy of our embryonic-like ECM proteins in vivo and about the range of potential applications of the hECM, such as a biopsy needle coating, and as a post-resection tissue filler to improve healing and to prevent possible recurrence or metastasis."

The inhibitory affect of the hECM is selective for malignant cells, supporting fibroblast expansion while concurrently inhibiting mesothelioma cells in vitro. Preliminary indications point to the activation of apoptotic enzymes, as seen through caspase upregulation, leading to apoptosis, or programmed cancer cell death.

"Human embryonic-like ECM stimulates proliferation and differentiation in stem cells while killing cancer cells" will be presented by Histogen CEO Dr. Gail Naughton at the ISSCR Annual Meeting, taking place June 16-19, 2010 in San Francisco.

About Histogen
Histogen, launched in 2007, seeks to redefine regenerative medicine by developing a series of high value products that do not contain embryonic stem cells or animal components. Through Histogen's proprietary bioreactors that mimic the embryonic environment, newborn cells are encouraged to naturally produce the vital proteins and growth factors from which the Company has developed its rich product portfolio. Histogen has two product families - a proprietary liquid complex of embryonic-like proteins and growth factors, and a human Extracellular Matrix (ECM) material, ExCeltrix. For more information, please visit http://www.histogen.com.

###

Read the full story at http://www.prweb.com/releases/histogen/oncology/prweb4155854.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related biology technology :

1. Expiry of Hart-Scott-Rodino Waiting Period for JUVISTA(R) (Human TGF BETA 3)
2. New Initiative Has Shocking Effect: Thousands of Missourians with Abnormal Chromosome Structures Are Not Human
3. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
4. Human Genome Sciences Announces $40 Million Milestone Payment Related to Albuferon(R) Development
5. Novocell Announces Discovery Linking Key Cancer Cell Signaling Pathways With Proliferation and Self-Renewal of Human Embryonic Stem Cells
6. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Thomas Weisel Partners Conference
7. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at BioCentury-Thomson Financial Investment Conference
8. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Bear Stearns Conference
9. Human Pheromone Sciences Enters Into Agreement to Reposition and Promote its Natural Attraction(R) Brand
10. Human Genome Sciences Invites Investors to Listen to Webcast of Presentation at Merrill Lynch Conference
11. Premier Research Appoints Global Head of Human Resources
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Human Embryonic-Like Extracellular Matrix Significantly Inhibits Tumor Growth and Cancer Cell Proliferation 
(Date:10/11/2017)... ... October 11, 2017 , ... The CRISPR-Cas9 ... enabling overexpression experiments and avoiding the use of exogenous expression plasmids. The simplicity ... for performing systematic gain-of-function studies. , This complement to loss-of-function studies, such ...
(Date:10/11/2017)... Alto, CA, USA (PRWEB) , ... October 11, 2017 , ... ... set to take place on 7th and 8th June 2018 in San Francisco, CA. ... policy influencers as well as several distinguished CEOs, board directors and government officials from ...
(Date:10/11/2017)... INDIANAPOLIS , Oct. 11, 2017  VMS BioMarketing, a ... of a nationwide oncology Clinical Nurse Educator (CNE) network, which ... growing need for communication among health care professionals to enhance ... physicians, nurses, office staff, and other health care professionals to ... for breast cancer. ...
(Date:10/11/2017)... Tbilisi, Georgia (PRWEB) , ... October 11, 2017 , ... ... disaster, taking the lives of over 5.5 million people each year. Especially those living ... the greenovative startup Treepex - based in one of the most pollution-affected countries globally ...
Breaking Biology Technology:
(Date:4/11/2017)... , Apr. 11, 2017 Research and Markets ... 2017-2021" report to their offering. ... The global eye tracking market to grow at a CAGR ... Global Eye Tracking Market 2017-2021, has been prepared based on an ... the market landscape and its growth prospects over the coming years. ...
(Date:4/5/2017)... Today HYPR Corp. , leading innovator ... of the HYPR platform is officially FIDO® Certified ... architecture that empowers biometric authentication across Fortune 500 enterprises ... over 15 million users across the financial services industry, ... product suites and physical access represent a growing portion ...
(Date:3/30/2017)... HONG KONG , March 30, 2017 ... developed a system for three-dimensional (3D) fingerprint identification by adopting ground ... technology into a new realm of speed and accuracy for use ... applications at an affordable cost. ... ...
Breaking Biology News(10 mins):